Last reviewed · How we verify

Recombinant Influenza Vaccine

Insight Therapeutics, LLC · FDA-approved active Biologic Quality 5/100

Recombinant Influenza Vaccine is a Biologic drug developed by Insight Therapeutics, LLC. It is currently FDA-approved. Also known as: Flublok, RIV4, FluBlok.

At a glance

Generic nameRecombinant Influenza Vaccine
Also known asFlublok, RIV4, FluBlok
SponsorInsight Therapeutics, LLC
ModalityBiologic
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Recombinant Influenza Vaccine

What is Recombinant Influenza Vaccine?

Recombinant Influenza Vaccine is a Biologic drug developed by Insight Therapeutics, LLC.

Who makes Recombinant Influenza Vaccine?

Recombinant Influenza Vaccine is developed and marketed by Insight Therapeutics, LLC (see full Insight Therapeutics, LLC pipeline at /company/insight-therapeutics-llc).

Is Recombinant Influenza Vaccine also known as anything else?

Recombinant Influenza Vaccine is also known as Flublok, RIV4, FluBlok.

What development phase is Recombinant Influenza Vaccine in?

Recombinant Influenza Vaccine is FDA-approved (marketed).

Related